Global RNA Targeting Small Molecule Drug Discovery Market Size Likely to Grow at a CAGR of 22.1% By 2035

The market size of the global RNA targeting small molecule drug discovery will be estimated at USD 2.4 billion in 2025 and is expected to grow between USD 2.9 billion in 2026 and about USD 17.6 billion by 2035 with a current CAGR of 22.1% during the period of 2026 to 2035.

RNA Targeting Small Molecule Drug Discovery Market Revenue and Trends

RNA-targeting small-molecule drug discovery is the process of revealing and making up low-molecular-weight chemical compounds with the purpose of selectively binding to and modifying the structure or function of RNA that is going to produce therapeutic effects. This method is completely different from the traditional drug discovery which is mainly focused on proteins. Targeting RNA elements directly was the way to go and this included genes that were responsible for expression, splicing, translation, and RNA–protein interactions. Also, mRNA and the non-coding RNAs were included.

By changing the RNA behavior, small molecules can restore the normal genetic regulation and thus cure the disease, change the abnormal cellular pathways, or even take care of the targets that were previously thought to be "undruggable". The RNA-targeting small-molecule drug discovery strategy made use of the progress in the aforementioned areas and is being applied more and more in oncology, neurological disorders, rare genetic diseases, and infectious diseases. It is now considered a next-generation therapeutic modality.

What are the Factors That Have a Significant Contribution to the Growth of the RNA Targeting Small Molecule Drug Discovery market?

The technology and screening improvements are to a great extent responsible for the growth of the RNA-targeting small-molecule drug discovery market. These technologies enhance the productivity, precision, and the overall success rates of the entire RNA-centric drug development process. A variety of advanced methods like high-throughput RNA screening platforms, cell-based functional assays, and cutting-edge chemo proteomics tools are allowing the researchers to find the right small molecules that selectively bind to the RNA and also have a significant biological activity in just a few days. Such technologies have facilitated conducting drug discovery with all the process features of being faster and more accurate at the same time due to the removal of the limitation imposed by the intricate structure and variable nature of RNA.

At the same time, the combination of the AI-based computational modeling for drug design and the structure-informed methodology has led to a considerable speed-up in the lead optimization process since among the steps it includes are predicting the RNA structures, recognizing the binding sites with drug potential, and improving the selectivity and pharmacokinetic properties. All these technological and screening strides taken together result in shorter detection times, lower R&D costs, and less wastage of new products that are just at the early stages of development. The pharmaceutical and biotechnology companies are not just using these last-generation tools but are also increasing their trust in the RNA-targeting approaches slowly, which in turn results in the wider adoption, stronger pipelines, and the enduring growth of the market.

Segment Insight

By Indication

The metabolic diseases segment is growing at a significant rate over the projected period. The principal cause of this increase is the greater global prevalence of diseases like diabetes, obesity, NAFLD, and hereditary metabolic disorders. There are several metabolic disorders that result from the alteration of gene expression, abnormal RNA splicing, and modification of RNA–protein interactions that influence crucial metabolic pathways. A new method to silence or activate these changes at the RNA level is to use small compounds that target RNA, which in turn allows for a more exact intervention than the traditional protein-centered treatments.

Regional Insights

The RNA targeting small molecule drug discovery market has been dominated by North America. The growth in revenue can be attributed to the wide availability of funding including venture capital, government-sponsored research grants, and partnerships between pharmaceutical and biotech companies that reduce the risk of early-stage RNA programs and hasten their commercialization.

Besides, the Asia Pacific market has the highest rate of growth in the RNA targeting small molecule drug discovery market. The major and expanding patient group that is affected by cancer, metabolic disorders, neurological diseases, and rare genetic disorders is the main source of the revenue growth that has been driving the demand for innovative, cost-effective therapies. On top of that, the Asia Pacific region has the advantage of incurring lesser costs for R&D and clinical trials which in turn leads to the quicker and cheaper transitioning of RNA-targeting small molecules from the discovery phase to early-stage development.

Report Scope

Recent Developments

• In December 2025, Arrakis Therapeutics, a biopharmaceutical company that is engaged in the discovery of a new class of small molecule medicines that directly target RNA, announced the presentation of preclinical data which are going to show the development of its RNA-targeted small molecule (rSM) drug program for the treatment of myotonic dystrophy type 1 (DM1), which is a kind of muscular dystrophy. The oral administration of the rSMs of the company’s leading series not only achieved broad biodistribution but also corrected mRNA splicing as well as myotonia in an in vivo animal model of the disease. The data are being presented today at the 8th Annual RNA-Targeted Drug Discovery and Development Summit, which is going to be held in Boston, MA from December 2-4, 2025. (Source: https://arrakistx.com/press-release/arrakis-therapeutics-presents-data-highlighting-progress-of-oral-rna-targeted-small-molecule-to-treat-myotonic-dystrophy-type-1-dm1/)

List of the prominent players in the RNA Targeting Small Molecule Drug Discovery Market:

• ACCENT THERAPEUTICS

• LES LABORATOIRES SERVIER

• Arrakis Therapeutics

• AstraZeneca

• Epics Therapeutics

• Expansion Therapeutics

• F. Hoffmann-La Roche Ltd

• PTC Therapeutics Inc.

• Ribometrix

• Anima Biotech Inc.

• Skyhawk Therapeutics

• Others

The RNA Targeting Small Molecule Drug Discovery Market is segmented as follows:

By Indication

• Cancer

• Metabolic Diseases

• Infectious Diseases

• Neurological Diseases

• Others

By End Use

• Academic and Research Institutes

• Pharmaceutical and Biopharmaceutical Companies

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America